Evidence map›Paper›PMID 38680575›Full record

ReviewAsian journal of urology2024

A systematic review of cytoreductive prostatectomy outcomes and complications in oligometastatic disease.

Andrey Morozov, Leonid Chuvalov, Mark Taratkin, Mikhail Enikeev, Leonid Rapoport, Nirmish Singla, Eric Barret, Elena Poddubskaya, Maria Borodina, Georg Salomon and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Andrey MorozovInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Leonid ChuvalovInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Mark TaratkinInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Mikhail EnikeevInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Leonid RapoportInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Nirmish SinglaDepartment of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, USA.
Eric BarretDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Elena PoddubskayaSechenov University, Moscow, Russia.
Maria BorodinaHertsen Moscow Oncology Research Institute, Moscow, Russia.
Georg SalomonMartini Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Juan Gomez RivasDepartment of Urology, Clinico San Carlos University Hospital, Madrid, Spain.
Dmitry EnikeevInstitute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To analyze outcomes and complications of cytoreductive prostatectomy (CRP) for oligometastatic prostate cancer (PCa) in order to elucidate its role in this space. Methods: We performed a systematic literature search using three databases (Medline, Scopus, and Web of Science). The primary endpoints were oncologic outcomes. The secondary endpoints were complication rates and functional results. Results: In all studies, overall survival was better or at least comparable variable in the groups with CRP compared to no local treatment. The greatest benefit from CRP in 5-year overall survival in one study was 67.4% for CRP versus 22.5% for no local treatment. Cancer-specific survival (CSS) showed the same trend. Several authors found significant benefits from CSS in the CRP group: from 79% Conclusion: CRP improves medium-term cancer control in patients with oligometastatic PCa. The morbidity and complication rates of this surgery are comparable with other approaches, but postoperative incontinence rate is higher compared with RP for localized disease.

Indexed as

Bone metastasesCytoreductive prostatectomyOligometastaticProstate cancerSystematic review

Identifiers

PMID38680575
PMCPMC11053306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.